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Abstract 
Background: Changes in the tumor microenvironment and immune surveillance represent crucial hallmarks of vari-
ous kinds of cancer, including oral squamous cell carcinoma (OSCC), and a close crosstalk of hypoxia regulating genes, 
an activation of chemokines and immune cells has been described.
Methods: A review about the pivotal role of HIF-1, its crosstalk to various cornerstones in OSCC tumorigenesis is 
presented.
Results: Hypoxia is a frequent event in OSCC and leads to a reprogramming of the cellular metabolism in order to 
prevent cell death. Hypoxic OSCC cells induce different adaptive changes such as anaerobic glycolysis, pH stabilisa-
tion and alterations of the gene and protein expression profile. This complex metabolic program is orchestrated by 
the hypoxia inducible factor (HIF)-1, the master regulator of early tumor progression. Hypoxia-dependent and -inde-
pendent alterations in immune surveillance lead to different immune evasion strategies, which are partially mediated 
by alterations of the tumor cells, changes in the frequency, activity and repertoire of immune cell infiltrates and of 
soluble and environmental factors of the tumor micromilieu with consecutive generation of an immune escape phe-
notype, progression of disease and poor clinical outcome of OSCC patients.
Conclusions: This review focusses on the importance of HIF-1 in the adaption and reprogramming of the metabolic 
system to reduced oxygen values as well as on the role of the tumor microenvironment for evasion of OSCC from 
immune recognition and destruction.
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Characteristics of oral squamous cell carcinoma 
and additional prognostic markers
Oral squamous cell carcinoma (OSCC) are among the 
ten most frequent human malignancies and mostly arise 
in the context of alcohol abuse and smoking while HPV 
infection does not play an important role in carcinogen-
esis of this disease [1]. As for the oral cavity SCCs, many 
authors reported frequent high-risk HPV involvement by 
considering the over-expression of p16INK4A as equiva-
lent to HPV infection [2, 3]. Nevertheless, recent data in 
oral cancers indicate that p16INK4A over-expression is 
due to different mechanisms and high-risk HPV infection 
is very rarely detectable in OSCCs [2, 4, 5].
Despite some progress in diagnostics and therapeutic 
options the 5-years overall survival rate (OSR) stagnates 
up to only 40–50 % over a 40-years period [6–9].
However, the routinely used tumor stratification 
based on the tumor, node, metastasis (TNM) classifica-
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sufficient to predict the individual prognosis of an OSCC 
[10, 11]. Therefore, there is an urgent need to establish 
additional prognostic factors. Interestingly, the aggres-
siveness of OSCC increased with aboral localization. Fur-
thermore, systematic analysis of the expression profiles of 
OSCC led to the identification of different tumor markers 
with prognostic value in OSCC, such as the carcinoem-
bryonic antigen (CEA), carbonic anhydrase (CA) 19–9, 
CA 125, CA 15–3 and the squamous cell carcinoma (SCC) 
antigen [12]. Recently, also hypoxia-associated genes were 
identified as important markers for prognosis of OSCC 
[10, 13] suggesting that hypoxia-dependent pathways 
including the stabilization of HIF-1α play a key role in 
the development and progression of this disease [14–16]. 
So far, the expression and localization of HIF-1α, the key 
regulator of hypoxic responses, in OSCC cells have been 
determined by several groups, although the downstream 
effects in particular the expression of hypoxic pathways 
in the context of OSCC progression are widely unknown. 
In addition, the different cellular processes controlling the 
composition of immune cell infiltration and immune sur-
veillance have to be elucidated to develop novel prognos-
tic markers and potential therapeutic strategies. Recently, 
the molecular mechanisms and signal transduction path-
ways involved in the development of head and neck squa-
mous cell carcinoma (HNSCC) in general and of OSCC 
in particular have extensively reviewed [17, 18]. Therefore, 
this survey summarizes the molecular biologic and immu-
nologic aspects involved in OSCC with a specific focus on 
the hypoxic tumor microenvironment and its link to an 
altered tumor metabolism.
Tumor hypoxia and prognosis in OSCC
HIF‑1—a key regulator protein in cancer progression
All mammalian cells require oxygen for their essential 
metabolic program including oxidative phosphoryla-
tion [19, 20]. The normal physiological oxygenation of 
mammalian tissues varies between 1 and 11 % (approxi-
mately partial pressures of 7.5–85  mm  Hg) [21, 22]. 
Intra-tumoral hypoxic stress could be mediated by rapid 
cell division, aberrant angiogenesis and blood flow. An 
oxygen pressure below 5–10 mm Hg is a powerful force 
for metabolic adaption and leads to structural altera-
tions favouring survival, angiogenesis and progression 
of tumors, epithelial-mesenchymal transition (EMT), 
suppression of immune reactivity, which then correlated 
with poor prognosis and therapy resistance of tumor 
patients [23–25]. Hypoxic stress induces a complex gene 
expression program [26, 27] with HIF-1 as a master tran-
scriptional regulator of genes controlling oxygen home-
ostasis [28], thereby mediating cellular and systemic 
adaptive responses to maintain oxygen homeostasis in all 
metazoan species [29].
The HIF system consists of three principal molecule 
groups: The most important molecule is HIF-1, which 
contains the oxygen sensing subunit alpha (HIF-1α). Next 
to HIF-1α HIF-2α and various homologues of HIF-3α 
have been identified [24, 28, 30, 31]. Despite HIF-2α is 
also regulated by an oxygen-dependent hydroxylation 
[24], it is not involved in all types of cancer [32, 33]. In 
some carcinoma, an inverse expression of HIF-1α and 
HIF-2α was found. While HIF-1α is overexpressed and 
associated with disease progression in HIF-2α expression 
is low and is a good prognostic marker [34]. In contrast, 
the third homologue, HIF-3α, may function as an inhibi-
tor of both HIF-1α and HIF-2α [24].
HIF-1 is a basic helix-loop-helix-PAS heterodi-
mer composed of an alpha and a beta subunit [19, 22]. 
The beta subunit, also called aryl hydrocarbon recep-
tor nuclear translocator (ARNT), is a constitutively 
expressed 91–94  kDa protein [20, 30]. Under physi-
ologic conditions HIF is hydroxylated by specific prolyl 
hydroxylases (PDH) on proline residues 402 (Pro-402) 
and 564 (Pro-564), which facilitates the binding of the 
von Hippel-Lindau tumor suppressor protein (pVHL) to 
HIF-1α/HIF-2α leading to a rapid ubiquitination by an 
E3-ubiquitin ligase complex followed by the proteaso-
mal degradation of HIF1α/HIF2α [32]. Another possibil-
ity to inhibit HIF-1α is mediated by the factor inhibiting 
HIF-1 (FIH-1α), which hydroxylates asparagine 803 in 
the transactivation domain and consequently blocks the 
binding of the co-activators p300 and CBP [28]. Under 
hypoxic conditions, HIF-1α dimerizes with HIF-1β and 
the resulting transcription factor HIF1 activates a large 
panel of target genes. HIF-1α represents a central protein 
involved in different pathways that are important for the 
survival of cancer cells in early cancer disease progres-
sion. Recently, a meta-analysis of 28 studies was per-
formed on a large cohort of overall head and neck cancer 
(HNC) patients demonstrating an association of HIF-1α 
and HIF-2α overexpression with mortality particularly in 
the Asian population wherein increased levels of HIF-1α 
were associated with a reduced survival [15]. This meta-
analysis further clarified that HIF-1α expression has a 
distinct prognostic value in the different subtypes and 
localization of HNC [15] indicating that the different 
subtypes of HNC should be analysed separately. Con-
cerning OSCC increased HIF-1α levels have been shown 
to correlate with poor prognosis [14, 35–37].
HIF‑1α target genes
A more general finding was first proposed by Semenza 
and co-workers demonstrating that HIF-1α controls the 
expression of 100 genes involved in tumor progression 
[38] and this number increased to more hundred genes 
during the last years [39]. These genes include the CAIX, 
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a membranous enzyme involved in pH regulation [40] 
the glucose transporter-1 (GLUT-1) responsible for glu-
cose import [41] and the monocarboxylate transporter-1 
(MCT-1) and MCT-4 important for lactate transport [42, 
43]. Furthermore, HIF-1 targets are not only involved in 
glucose transport and glycolysis, but also in cell survival 
and proliferation, invasion and metastasis formation [24]. 
This is in line with reports describing a hypoxia-medi-
ated “angiogenic” or “glycolytic” switch of tumor cells 
[44]. Furthermore, a continuous low O2 partial pressure 
has an impact on both the cellular metabolism and HIF 
signaling [22]. The HIF-1-mediated pathways, which play 
an important role in stabilization and/or progression of 
OSCC lesions, are (i) glycolysis (ii) angiogenesis (iii) pH 
stabilisation (iv) the microenvironment and epithelial 
mesenchymal transition (EMT) and (v) distinct strategies 
of tumor cells to escape immune surveillance (Fig. 1).
Role of glycolysis
Hypoxia induces adaptive changes in the cellular metab-
olism by HIF-1 as a master regulator to balance oxygen 
supply and demand [34]. OSCC cells obtain most of their 
energy by glycolysis. Since glycolysis delivers only 2 ATP 
molecules compared to 38 ATP molecules by respira-
tion, an increased glucose uptake is essential for tumor 
cells to survive [45]. The family of glucose transporter 
molecules summarizes 13 members [46, 47]. The most 
investigated transport molecules in OSCC are HIF1 and 
GLUT-1 [41, 48]. Own investigations demonstrated a 
significant correlation between increased glucose uptake 
and poor prognosis in OSCC [49]. Similar results were 
obtained by Harshani [48]. In addition, the hypoxia 
linked upregulation of GLUT-1 was also described by 
Gimm and co-authors, which negatively interfered with 
the survival of OSCC patients [50]. An increased glucose 
consumption leads to an acidification of tumor cells. The 
next crosstalk to enable tumor cell survival is an upregu-
lation of carbonic anhydrase(s). This was accompanied 
by co-expression of HIF-1α and CAIX, from which the 
latter is also transcriptionally activated by the HIF com-
plex. Interestingly, the risk of tumor-related death for the 
patients’ groups with the worst prognosis was compa-
rable independent of HIF-1α alone (RR =  4.53) [51]. In 
addition, GLUT-1 is overexpressed at a high frequency 
in OSCC lesions, patients with tumour lesions express-
ing both HIF-1 α and GLUT-1 had a 5.13-fold increased 
risk of tumour-related death (P = 0.017). Co-expression 
of high levels of HIF-1α and GLUT-1 was hence signifi-
cantly correlated with poor prognosis in OSCC patients. 
Since proteins associated with the glucose and lactate 
metabolism often co-localize in hypoxic areas of OSCC 
[52, 53], a combined analysis of the expression pattern 
of both proteins might be used as an early diagnostic 
and independent prognostic marker [54]. Moreover, 
enhanced glucose uptake by OSCC cells reduced the sen-
sitivity of tumor cells to cisplatin-based chemotherapy 
[55].
Role of angiogenesis
Tumor progression is a multifactorial process includ-
ing the induction of angiogenesis and cancer cell pro-
liferation in OSCC cells. This was accompanied by an 
upregulation of diverse angiogenic markers. Angiogenin 
expression significantly correlates with HIF-1α [56] and 
with an increased microvessel density (MVD). When 
OSCC cells were cultured under mild hypoxia (5  % O2) 
only HIF-2 α contributed to VEGF-expression. In con-
trast, at 1 % O2 VEGF’s were regulated by both HIF-1 α 
and HIF-2α. As a consequence both HIF-1α and HIF-2α 
play a pivotal role in tumor angiogenesis and tumor 
growth of OSCC [37]. In addition, HIF-1α is involved in 
tumor lymphoangiogenesis. This was demonstrated by 
analysis of the density of blood and lymphatic microves-
sels in OSCC using immunohistochemical staining for 
CD43 and LYVE-1: HIF-1α overexpression significantly 
correlated with a VEGF-C upregulation. Consequently, 
a higher lymphatic vessel density was found in HIF-1α-
positive OSCC [57].
Role of pH stabilisation
The proliferation of cancer cells creates toxic waste prod-
ucts and an acidification leading to a decrease in the 
intracellular pH of tumor cells. The metabolic adaption 
accumulates different ionic exchangers at the tumor cell 
membrane to maintain intracellular pH (pHe) (Fig.  2). 
Dysbalances in pHe have been shown to be associ-
ated with cancer progression [58]. Moreover, HIF-1α 
orchestrates also pH stability of the tumor cells [59] and 
extracellular matrix adaption [60, 61], which is linked 
to alterations of the metabolic program by affecting the 
expression of the HIF-regulated pathway components 
[59]. This includes e.g. an upregulation of CAIX, which 
is associated with nodal metastases and a decreased 
survival of OSCC patients [62]. The deregulated pH in 
OSCC is also an adaptive feature, which could be divided 
into general pathways. First it is necessary to maintain the 
intracellular pH (pHi). Second, an acidification of extra-
cellular pH (pHe) is the consequence. In normal differen-
tiated adult cells, intracellular pH (pHi) is generally ~7.2 
and lower than the extracellular pH (pHe) of ~7.4. How-
ever, cancer cells have a higher pHi of ≥7.4 and a lower 
pHe of ~6.7–7.1. A complex membrane spanning system 
is initiated to emerge pH homeostasis. In this process 
HIF-1α is a sensitive controller and regulator of a com-
plex adaptive metabolic response to alterations in par-
ticular the intracellular pH value [33, 62]. An increased 
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pHi is permissive for cell proliferation and the evasion of 
apoptosis, facilitates metabolic adaptation and is obliga-
tory for efficient directed cell migration [58]. It is pro-
posed that the hypoxic microenvironment induced the 
epithelial to mesenchymal transition (EMT), upgraded 
stem-like properties, promoted invasion and metastasis, 
and thus increased the malignancy. Several pluripotency 
transcription factors seem to be associated with the EMT 
transition process like Nanog and POU5F1, SNAI and 
SOX-2 [11, 63–66].
In our opinion, the same effects are another hallmark 
of OSCC development as described by Guo and co-
workers for gastric cancer [67, 68]. The HIF-1α-mediated 
hypoxia-dependent down-regulation of E-cadherin and 
upregulation of N-cadherin is caused by the activation of 
the transcription factor SNAI2 thereby promoting EMT 
of tumor cells. Therefore, the aberrant HIF-1α and SNAI2 
expression combined with the cadherin switch has been 
suggested as potential risk marker for predicting metas-
tasis and clinical prognosis [68]. Furthermore, the switch 
to anaerobic metabolism the genetic instability of OSCC 
cells greatly increases [44].
Tumor microenvironment 
and epithelial‑mesenchymal transition (EMT)
When hypoxia results in epithelial mesenchymal transi-
tion, the resultant reduction in adherence and the change 
of cytoskeleton enables migration leading to metasta-
sis. The hostile microenvironment, which is created by 
hypoxic events, combined with the presence of growth 











Fig. 1 General pathways in oral squamous cell carcinoma as down-
stream products after hypoxic stabilisation of HIF. GLUT-1 Glucose 
transport molecule -1, VEGF Vascular endothelial growth factor, NHE 
Natrium/hydrogen exchanger, MCT Monocarboxylate transporter, CA 
IX Carbonic anhydrase 9, PDL-1 Programmed cell death ligand, CTL 
Cytotoxic T lymphocyte
MCT CAIX NHE  1    NHE 1 
H2O + CO2 H+ + HCO3- 





Extracellular space = tumor stroma 
Tumor cell - intracellular 
← ←
Fig. 2 HIF-triggered complex system for pH stabilization. MCT Monocarboxylate exchanger, CAIX Carbonic anhydrase 9, NHE 1 Sodium/hydrogen 
exchanger
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leading to this complex transition. EMT is classified as 
three different subtypes based on different biological 
settings, which causes various functional consequences. 
Type 1 EMT is considered to be associated with implan-
tation, embryogenesis, and organ development. Type 
2 EMT occurs in organ fibrosis, whereas Type 3 EMT 
occurs in carcinogenesis [69]. During the progression 
to metastatic competence, the OSCC cells enter into a 
metabolic and survival reprogramming process. This 
allows the OSCC cells to acquire features similar to mes-
enchymal cells that may significantly impart invasiveness, 
changes in adhesive properties, activation of motility and 
the degradation of the extracellular matrix. Major signal-
ing pathways, which are commonly implicated in epithe-
lial-mesenchymal transition, include TGF-β, Wnt, Notch, 
Hedgehog, and others. These pathways converge on sev-
eral transcription factors, including zinc finger proteins 
Snail and SNAI2, Twist, ZEB1/2, and Smads. These fac-
tors interact with one another and others to provide 
crosstalk between the relevant signaling pathways [70].
Although hypoxia-induced EMT signalling occurs in all 
tumor cell populations, only the stem-like cells acquire 
high migratory potential, which suggests that these cells 
are potentially responsible for invasion and consequently 
metastasis [71]. Furthermore, in the presence of hypoxia, 
the utilization of epigenetic mechanisms of gene regula-
tion could play an important role in aggressive behaviour 
of tumors.
The tumor microenvironment appears to play a promi-
nent role in affecting EMT changes. For example, the 
E-cadherin transcriptional repressor, TWIST, is posi-
tively regulated by HIF-1α [72]. It has been demonstrated 
that hypoxia-induced EMT in in  vitro experiments is 
associated with increased HIF-1α and Twist expression 
that knock-down either HIF-1α or Twist blocks hypoxia-
induced EMT [73].
There are many pathways regulating EMT. Amongst 
them are Notch signaling and Wnt pathways, which 
have been shown to be involved in the conversion of the 
hypoxic stimulus into EMT. They are also important in 
Fig. 3 Complex system of adaption to hypoxic stress in early carcinogenesis (a) and mechanisms for immune escape (b)
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increasing both motility and invasiveness of the tumor 
cells [74]. The EMT program has been found to be 
active in the invasive front of OSCC. There is evidence 
of reduced E-cadherin expression at the invasive front 
of OSCC. Additionally, there is an association with his-
tological invasiveness, which suggests that this protein 
could be a potential EMT marker, thus offering prognos-
tic information in OSCC [75].
Moreover, there is further evidence that suggests 
hypoxia induced EMT in OSCC cell lines via activation 
through Notch signaling. Therefore, inhibition of the 
Notch signaling pathway to suppress EMT is possibly 
a useful approach for the treatment of OSCC [76]. An 
understanding in how hypoxia regulates EMT related 
transcriptome could help to identify nodes of interac-
tion related to cancer progression. Consequently, fur-
ther targeting hypoxia induced EMT could show to be an 
alternative therapeutic approach for the prevention and 
treatment of OSCC.
Distinct strategies of tumor cells to escape immune 
surveillance
A novel and recently emerging aspect in tumorigenesis 
is the crosstalk between hypoxia/HIF-1α and immune 
recognition/immune escape mechanisms [77]. Hypoxia 
has been shown to influence the repertoire and activ-
ity of immune cells in various tumor entities, including 
OSCC. Different strategies by which hypoxia contrib-
utes to tumoral immune escape from recognition by NK 
cells and cytotoxic T lymphocytes have been described 
[78–80].
Hypoxic stress is known to induce a variety of immune 
suppressive molecules, such as IL-10 and TGF-β (Figs. 3, 
4). This step could further induce the differentiation of 
tumor-associated macrophages (TAMs) into M2 mac-
rophages to suppress anti-tumoral activities [78]. In addi-
tion, HIF-1α orchestrates the CD4+ and CD8+ T-cells 
regarding their survival, apoptosis and cytokine secre-
tion. In HIF-knock down mice an increased frequency 
and activation of CD4+ and CD8+ T cells was found, 
which produced higher levels of IFN-γ thereby enhancing 
anti-tumor responses [81]. Furthermore, the interaction 
of HIF-1α with the cytotoxic T cell lymphocyte-antigen 
4 (CTLA-4) as immune checkpoint regulator and its 
receptors CD80/CD86 is well known. The HIF-triggered 
CTLA-4 blockade caused a reduction in the frequency of 
tumor infiltrating Tregs [78]. Another key role of HIF-1α 
associated with immune escape and induction of toler-
ance is the shedding of cell surface immune checkpoint 
regulators like MICA, which interact with the NKG2D 
receptors of different immune cells. Tumor cytolysis is 
avoided due to the resistance to NK cell attack [82]. This 
immune adaption is dependent on the HIF-1α-mediated 
induction of metalloproteinase ADAM-10 in tumor cells 
[83].
In addition, PDL-1 is expressed under hypoxic condi-
tions leading to resistance to CTL-mediated lysis. More-
over, the cellular co-localisation of HIF-1α and PDL-1 
in tumors has been well investigated [79]. In advanced 
OSCC Chen and co-workers described positive staining 
for both HIF-1α and PDL-1, which was associated with 
a worse prognosis [84]. In addition, a binding of HIF-1α 
to the hypoxia-response element of the PDL-1 promoter 
has been shown in both breast and prostate cancer cell 
lines demonstrating a link of HIF-1α with the checkpoint 
inhibitor [79].
It is generally accepted that tumor cells could be recog-
nized as abnormal cells and thus be destroyed by immune 
cells. However, tumors have developed different mecha-
nisms that allow their immune escape such as deficient 
expression of tumor antigens on their cell surface, loss or 
a reduced expression of MHC (major histocompatibility 










Fig. 4 Differential expression of hypoxia markers and HLA class I 
in OSCC-carboanhydrase (CA) IX1, hypoxia inducing factor (HIF) 1α2, 
beta2-microglobulin (β2-m)3 and heavy chain (HC)-104 in human 
head and neck squamous cell carcinoma (OSCC)
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complex) class I molecules, lack of expression of co-stim-
ulatory molecules, production of immune suppressive 
molecules like the transforming growth factor (TGF)-β, 
IL-6, IL-10, prostaglandin (PG) E2 and adenosine, resist-
ance to apoptosis, and/or the expression of Fas ligand 
(FasL), which leads to the death of tumor-infiltrating 
lymphocytes (TILs) as well as induction of co-inhibitory 
molecules of the B7 family and of non-classical HLA class 
I antigens, e.g. HLA-G and HLA-E [85–88]. In addition, 
tumor cells can recruit TAMs, the major inflammatory 
components of the tumor microenvironment by secret-
ing the colony stimulating factor (CSF-1), the chemokine 
ligands 2, 3, 4, 5, and 8 (CCL2, 3, 4, 5, and 8) and VEGF 
[89–91]. Due to their distinct functions macrophages 
could be divided into (i) the M1 phenotype, which kill 
pathogens, promote the activation of cytotoxic CD8+ T 
cells and the differentiation of naïve CD4+ T cells into 
Th1 effector and Th17 cells and (ii) the M2 macrophages, 
which stimulate CD4+ Th2 cells as well as regulatory T 
cell differentiation and promote angiogenesis and tis-
sue remodeling (pro-tumor functions). The effect of 
Th17 cells is controversially discussed. However, so far 
no information exists on the prognostic impact of pre-
malignant oral lesions developing OSCC and their TAM 
phenotype. It might be an advantage to limit the progres-
sion of premalignant lesions to cancer by sustaining the 
Th17 phenotype [92]. This is in contrast to Deng and co-
authors demonstrating a recruitment and proliferation of 
Th17 cells in the intestine promoting colon cancer [93]. 
Multiple studies demonstrated a correlation between 
the frequency of macrophages in the tumor microenvi-
ronment and the patients’ prognosis. This is due to the 
secretion of the epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), TGF-β, IL-6, IL-1, and 
tumor necrosis factor (TNF)-α of TAMs, which creates 
a favorable milieu for tumor growth. In hypoxic areas, 
TAMs stimulate angiogenesis by secreting TGF-β, VEGF, 
granulocyte macrophage (GM)-CSF, TNF-α, IL-1, IL-6, 
and IL-8, promote tumor cell migration and invasion via 
matrix metalloproteinases (MMPs), TNF-α, and IL-1 and 
induce immunosuppression via TGF-β, PGE2, and IL-10. 
T lymphocytes could also contribute either to tumor 
cell destruction or facilitate its development. While Th1 
CD4+ T cells facilitate tumor rejection by assisting the 
function of cytotoxic CD8+ T cells, Th2 CD4+ T cells 
promote antibody production of B cells by secreting 
cytokines. The CD4+ T regulatory cells (Tregs) express-
ing FoxP3 promote tumor progression by inhibiting the 
NK and T cell functions. Their frequency is increased in 
tumor patients and associated with a worse prognosis. 
In addition, the number of myeloid-derived suppressor 
cells (MDSCs), which are induced by VEGF, GM-CSF, 
TGF-β, IL-6, PGE2, and cyclooxygenase (COX)-2 are 
often increased in tumor patients. MDSCs are a hetero-
geneous population of immature and progenitor myeloid 
cells with an immunosuppressive role in various types of 
cancer, including OSCC. A significant accumulation of 
both granulocytic and monocytic MDSC was observed 
in head and neck cancer. The frequency of granulocytic 
MDSC showed an inverse correlation to the frequency 
of T cells in the peripheral blood. The increased granu-
locytic MDSC significantly associated with advanced 
clinical stage and poor prognosis of head and neck cancer 
patients [94]. Cetuximab treatment of HNSCC signifi-
cantly increased monocytic MDSC in non-responders, 
but decreased granulocytic MDSC in responders of 
HNSCC patients. The frequency of MDSC known to pro-
mote tumor progression correlate with poor prognosis in 
cancer patients including HNSCC [95].
They have been shown to be involved in tumor pro-
gression by inhibiting the activity of CD4+ and CD8+ T 
cells, by the production of arginase and reactive oxygen 
species (ROS) and by inducing Tregs through an IL-10 
and IFN-γ-dependent process. Their interaction with 
macrophages could result in the induction of the type 2 
phenotype due to increased IL-10 secretion.
Peripheral blood markers reflecting the immunologic 
tumor microenvironment
One possibility to analyze the aggressiveness of OSCC is 
the identification of prognostic biomarkers in the periph-
eral blood. Indeed, a number of circulating biomarkers 
have been described [96]. These include e.g. circulating 
peripheral blood CD14+/CD16+ monocyte-derived 
macrophages (MDMs), which have been evaluated in 
OSCC patients by Grimm and co-workers and character-
ized as CD14+/CD16+ MDMs [97]. Moreover, the low-
est ratio of IL-17F/VEGF was found in OSCC patients 
(P   <   0.05): The lower ratio of IL-17F/VEGF correlated 
to higher tumor stage and lymph node metastases. Fur-
thermore, the serum level of IL-17F and the ratio of IL-
17F/VEGF were positively associated with the number 
of CD3+ CD4+ T cells. These data indicated that serum 
IL-17F might originate from PBMCs during the devel-
opment of OSCC and thus could be used to distinguish 
OSCC patients from healthy individuals [98]. The pro-
portion of CD57+ T cells, including both CD8+ and 
CD4+ subsets significantly increased with clinical stage, 
especially in parallel with tumor size as described by 
Iida and co-authors. The population of CD57+ T cells is 
another potent prognostic marker and may also influ-
ence the systemic immunity of patients with OSCC [99]. 
Moreover, different serum levels of IL17A, TGFβ1, IL4 
and IL10 were significantly higher in oral cancer patients, 
while the concentration of IL2 and IFN-γ was relatively 
lower in patients when compared to controls. TGFβ1 
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levels significantly correlated with disease. In this con-
text, IL17A might represent a risk factor for OSCC [100].
Characteristics of the immune escape in OSCC
It has been proposed that OSCC could escape the anti-
tumor response by several distinct mechanisms. So far 
alterations in the HLA class I molecules due to defi-
cient expression of components of the antigen process-
ing machinery (APM) has been mainly described thereby 
leading to resistance to CTL-mediated lysis. In HNSCC 
a coordinated downregulation of various APM compo-
nents, in particular TAP1, TAP2, tapasin and HLA class 
I antigens, were found with higher frequency of down-
regulation in metastasis when compared to the primary 
lesions of the same patients [101, 102]. This was further 
associated with a worse clinical outcome of patients. 
Furthermore, a downregulation of HLA class I antigens 
and of most APM components in OSCC lesions was 
described when compared to adjacent normal tissues. 
The deficient expression of the low molecular weight pro-
tein LMP2, a component of the proteasome, was associ-
ated with a reduced CD8+ T cell infiltration, which was 
associated with the presence of regional lymph node 
metastases and with reduced survival rates of these 
patients. The molecular mechanism of APM deficiencies 
in OSCC could be diverse and include ganglioside-medi-
ated or transcriptional-mediated down-regulation of sev-
eral HLA class I APM components [103, 104]. In addition 
a lack of IFN-γ inducibility has been shown as well as 
defects in the IFN-γ signal transduction pathway, such as 
impaired phosphorylation of one or more components, 
which also negatively interfere with the constitutive HLA 
class I APM component expression.
Furthermore, the development of OSCC is strongly 
influenced by the host immune system, such as reduced 
frequency of (activated) immune effector cells, increased 
frequency of regulatory T cells (Treg), functional defects 
or apoptosis of both circulating and tumor-infiltrating T 
cells and the local microenvironment disabling TIL due 
to absent or low expression of the CD3 zeta chain (CD3ζ), 
decreased proliferation in response to mitogens or IL-2, 
an imbalance in the cytokine profile and pronounced 
apoptotic features [105–108]. Moreover, immune cell 
dysfunction is also found in peripheral circulating mono-
nuclear cells of patients with advanced OSCC. HNSCC 
cells also produce high quantities of TGF-β1, which 
reduces the expression of NK cell receptor NKG2D and 
CD16 and inhibits the biological functions of NK cells. 
In addition, an accumulation of Tregs and TAMs in the 
TILs and/or of peripheral blood mononuclear cells in 
head and neck cancer patients was detected, which could 
be related to the early recurrence and patient’s prognosis 
[109–111]. High levels of various soluble mediators were 
found in the peripheral blood and/or tumor microenvi-
ronment of HNSCC, such as VEGF, PGE2, TGF-β, IL-6, 
and IL-10. These factors have been shown to inhibit the 
immune response at different levels.
Accumulating evidence exists that myeloid-derived 
cells including myeloid derived suppressor cells, poly-
morphonuclear granulocytes (PMN) and dendritic cells 
play an important role in tumor angiogenesis [112–114]. 
The frequency and function of these cells are modulated 
by tumor-derived factors thereby increasing the inflam-
matory or immune suppressive activity [115]. In addi-
tion, OSCC have also a significant impact on dendritic 
cells (DCs). A larger number of DCs in non-metastatic 
lymph nodes was found when compared to metastatic 
lymph nodes of OSCC. The immature DC marker CD1a 
was especially present in the cancer “nest”, whereas the 
mature DC marker CD83 was more prominent in the per-
itumoral area. The relationship between the expression 
of VEGF and DC infiltration, which plays an important 
role in immune defense against tumors, remains unclear. 
However, VEGF-A expression is not only involved in 
tumor angiogenesis, and disease progression but also in 
immune suppression by inhibiting the differentiation of 
CD1a+ immature DCs from progenitor cells leading to a 
reduced number of mature DCs and increased levels of 
dysfunctional CD83+ mature DCs [116]. Moreover, in 
OSCCs a greater number of S100+ and CD1a+ imma-
ture DCs in adjacent tissue and regional lymph nodes in 
patients without metastasis had been found. In contrast, 
CD83+ mature DCs were more abundant in patients with 
metastasis [117].
Tumor cells can modulate the expression of toll like 
receptors (TLRs) present on the surface of immune 
cells. Monocyte-derived DCs (MDCs) of OSCC patients 
express all TLRs except TLR4, -9, and -7 [118–120]. 
Thus altered TLR expression is an important tumor-
promoting event in OSCC progression. OSCCs can also 
influence the frequency of circulating MDC and plasma-
cytoid dendritic cell populations. The number of circulat-
ing MDCs (LIN-DR+CD11c+) was significantly lower in 
patients with OSCC. However, the circulating MDC pop-
ulation increased after removal of the tumor suggesting 
that this reduction was reversible and controlled by the 
presence of tumor cells. In addition, TAMs are involved 
in the angiogenesis and tumor progression of OSCC as 
described by various groups. The number of TAMs as 
determined by immunohistochemical analysis using the 
CD68 antibody is higher in carcinomas [121]. Compari-
son of TAMs with clinical parameters demonstrated an 
association between their frequency, tumor stage, grade 
and invasion, intratumoral microvessel density and the 
presence of angiogenic factors, such as VEGF [122]. This 
was further confirmed by the analysis of the expression 
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of cell cycle (cyclin E and p53) and proliferation mark-
ers (Ki-67) as well as macrophage infiltration [123]. A 
direct correlation between the macrophage infiltration 
and the tumor proliferation index was noted, which sug-
gested that the number of TAMs is functionally linked to 
tumor progression [124]. In addition macrophages play 
a role in OSCC formation by contributing to neovascu-
larization. In fact, OSCCs could attract macrophages by 
secreting MCP-1 and TGF-β1 [125, 126]. The mecha-
nisms responsible for T cell apoptosis in OSCC patients 
involve the Fas/FasL or the TRAIL and TNF-α signaling 
pathways. The FasL expression was found on the cell sur-
face of OSCC cells leading to an apoptotic signal of cir-
culating Fas+ T lymphocytes. The suppression of Treg 
might depend on Fas/FasL-mediated apoptosis: CD4+ T 
cells were resistant to Fas-mediated apoptosis by Tregs, 
but were able to induce Treg apoptosis in the presence of 
low concentrations of IL-2. The expression of monocyte 
chemotactic protein-1 (MCP-1/CCL2) and macrophage 
inflammatory protein-1α (MIP-1α/CCL3) was found in 
OSCC lesions and might also control disease progres-
sion. In addition, serum levels of CCL2 and CCL3 in 
OSCC were determined. A significant lower concentra-
tion of CCL2 was detected in the OSCC patients when 
compared to that in the healthy controls. Serum levels 
of CCL3 were positively related to the tumor size, while 
the CCL2/CCL3 ratio in OSCC patients was correlated 
to TNM (tumor, node, metastasis) [127, 128]. Thus CCL2 
and CCL3 are associated with progression of OSCC and 
might serve as potential biomarkers.
Clinical relevance of the frequency 
and composition of immune cell infiltrates
Recently, the prognostic value of various tumor-infiltrat-
ing immune cells populations was determined in OSCC 
patients. Interestingly, a high frequency of CD4+CD69+ 
T cells was linked to a better prognosis, and CD4+Foxp3+ 
T cells were positively correlated with better locoregional 
control. Moreover, a higher density of CD4+CD25+ Tregs 
was also linked to a good prognosis in OSCC. In discrep-
ancy to these studies the presence of Tregs in TILs was 
linked to a worse prognosis in OSCC patients in other 
reports. Suppression by the tumor microenvironment is 
mediated by a unique subset of CD4+CD25highFoxp3+ 
Tregs that produce IL-10 and TGF-β, which lead to a 
more antiproliferative effects [108, 129, 130]. Changes 
in the expression of the ζ chain of TILs are biologically 
significant because the absence or low expression of this 
chain in TILs in patients with stage III or IV HNSCC 
predicts a poor survival compared with patients express-
ing a normal ζ chain. The importance of the ζ chain was 
further confirmed by demonstrating a lower expression 
of the ζ chain in circulating CD4+ and CD8+ T cells and 
CD3−CD56+CD16+ NK cells in the blood of patients 
with OSCC when compared to healthy individuals. 
Reichert and co-authors studied the DC population and 
the expression of the ζ chain in TILs in a large series of 
132 OSCCs [131]. A low density of DCs and absent or 
low expression of the ζ chain in TILs was correlated with 
a poor prognosis of survival and a high risk of recurrence. 
The more advanced cases demonstrated higher rates of 
Tregs and B cells and fewer CD8+ T cells. In the low-risk 
group, a high concentration of CD20+ TILs was linked to 
a better survival rate, whereas this increase was linked to 
a worse prognosis in the high-risk group.
Conclusions
Although hypoxia has been associated with an increased 
immune escape a deeper understanding of the factors 
that cause immune suppression in OSCCs might be rel-
evant for the development of novel anti-cancer therapies. 
The worse prognosis of these patients has been linked to 
hypoxia and hypoxia-induced immune escape. Impaired 
anti-tumor responses of OSCC patients are caused by 
the tumor itself, by the presence of functional defects 
or apoptosis of both circulating and tumor-infiltrating 
T cells, but also by soluble factors of the tumor micro-
environment including soluble factors and the hypoxic 
microenvironment, which leads to an accumulation of 
immune suppressive cells, like TAM, Tregs and MDSCs 
macrophages as well as a downregulation in the function 
and activity of T lymphocytes and DCs.
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